433
Participants
Start Date
January 31, 2014
Primary Completion Date
May 31, 2017
Study Completion Date
May 31, 2017
Aldoxorubicin
Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
Herlev Hospital, Herlev
Roswell Park Cancer Institute, Buffalo
U of Pittsburgh Cancer Institute, Pittsburgh
Jefferson Medical College, Philadelphia
Istituto Europeo di Oncologia Milano, Milan
Wake Forest University Baptist Medical Center, Winston-Salem
Hospital Universitario La Paz, Madrid
Levine Cancer Institute, Charlotte
Hospital Puerta de Hierro Majadahonda, Majadahonda
Georgia Cancer Specialists, Atlanta
Complejo Hospitalario de Navarra, Pamplona
Mayo Clinic, Jacksonville
Moffitt Cancer Center, Tampa
Istituto Oncologico Veneto, Padua
University of Alabama at Birmingham, Birmingham
Vanderbilt University, Nashville
The James Cancer Hospital and Solove Research Institute, Columbus
University Hospitals Case Medical Center, Cleveland
Cleveland Clinic, Cleveland
University of Michigan, Ann Arbor
Medical College of Wisconsin, Milwaukee
University of Minnesota, Minneapolis
Mayo Clinic, Rochester
Edward Cancer Center, Naperville
Northwestern Medical Faculty Foundation, Chicago
Oncology Specialists, SC, Niles
Washington University, St Louis
Kansas City Cancer Center, Overland Park
Nebraska Methodist Hospital, Omaha
U of CO Health Sciences Center, Aurora
Rocky Mountain Cancer Centers, Denver
Arizona Oncology Associates, PC, Phoenix
The University of Arizona, Tucson
Samuel Oschin Cancer Center, Los Angeles
UCLA Medical Center, Los Angeles
City of Hope Medical Group, Duarte
Stanford University Medical Center, Stanford
Institut Gustave Roussy, Villejuif
Center for Health and Healing, Portland
"State Institution Blokhin Cancer Research Centre RAMS", Moscow
City Oncology Hospital #2, Moscow
Republican Clinical Oncologic Dispensary of Ministry of Health Republic Tatarstan, Tatarstan
Sarcoma Oncology Center, Santa Monica
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Fletcher Allen Health Care, Burlington
Royal North Shore Hospital, Saint Leonards
Westmead Hospital, Westmead
Cross Cancer Institute, Edmonton
Instituto Clinico Oncologica del Sur (ICOS), Temuco
Institut Bergonie, Bordeaux
Centre Leon Berard, Lyon
Centre Georges Francois Leclerc, Dijon
Centre Hospitalier Regional et Universitaire - Hospital Bretonneau, Tours
Hopital Rene Huguenin - Institut Curie, Saint-Cloud
Magyar Honvedseg Egeszsegugyi Kozpont, Budapest
Rambam Medical Center, Haifa
Sharet Institute of Oncology Hadassah Ein Karem Medical Center, Jerusalem
Chaim Sheba Medical Center, Ramat Gan
Tel Aviv Sourasky Medical Center, Tel Aviv
Fondazione del Piemonte per l'Oncologia, Candiolo
Azienda Ospedaliero-Universitaria di Bologna-Policlinico S Orsola-Malpighi, Bologna
IRCCS Instituto Ortopedico Rizzoli, Bologna
Instytut im.Marii Sklodowskiej-Curie, Warsaw
Consorcio Hospitalario Provincial de Castellon, Castellon
Inst Catala D'Oncologia, Barcelona
Centro Integral Oncologico Clara Campal, Hospital de Madrid Norte-San Chinarro, Madrid
Hospital San Carlos Madrid, Madrid
Hospital Universitario Miguel Servet, Zaragoza
Juravinski Cancer Center, Hamilton
McGill University, Montreal
Leiden Universitair Medisch Centrum, Leiden
Hospital Universitario Son Espases, Palma de Mallorca
Hospital Santa Creu i Sant Pau, Barcelona
Lead Sponsor
ImmunityBio, Inc.
INDUSTRY